Lifeboat Foundation

Another biomarker of senescent cells could be p16, a protein whose levels increase when cells stop dividing if old and also a protein whose gene is turned off in many human cancers.

Coming back to our topic – designing senolytics that avoid the apoptosis of young, healthy cells – the ideal senolytic should accomplish two things: –turn on p53 at increased levels to determine stubborn, senescent cells to commit suicide –do that on senescent cells only.

And in order to accomplish the second part, such a drug should be ‘programmed’ to only act on those cells where it recognizes senescence-associated biomarkers. There is no single biomarker today that stains positive or negative on all types of senescence cells, but increased levels of beta-galactosidase and p16 proteins could be a welcome start to identify old cells in vivo when designing such a drug.

Continue reading “How to avoid the adverse reactions of senolytics through better design” »

Genomic instability (mutations) has been suggested as being one of the primary hallmarks of aging and this research might support that idea. Researchers at John Hopkins report that around 66% of mutations in cancer cells are due to random errors with environment/lifestyle contributing 29% and 5% inherited.

“That finding challenges the common wisdom that cancer is the product of heredity and the environment. “There’s a third cause and this cause of mutations is a major cause,” says cancer geneticist Bert Vogelstein.”

“Such random mutations build up over time and help explain why cancer strikes older people more often. Knowing that the enemy will strike from within even when people protect themselves against external threats indicates that early cancer detection and treatment deserve greater attention than they have previously gotten, Vogelstein says.”

Continue reading “Random mutations play large role in cancer, study finds” »

A look at Rapamycin the life extending drug with some serious drawbacks.

If any drug has performed consistently and unequivocally well in anti-aging trials, it’s rapamycin. Dr. Matt Kaeberlein’s Dog Aging Project is among the most recent trials investigating its longevity-promoting potential in mammals, but it’s also been the subject of numerous trials in mice, worms, flies and yeast. And although it acts through a mechanism which has been most closely associated cancer prevention, this drug appears to stave off all maladies related to aging.

Even more encouraging are the indications that it could be beneficial well into old age. Trials done in the National Aging Institute’s ITP, a testing protocol that collects its data from three independent labs, found that when mice started rapamycin treatment at 600 days old (roughly 60 in human years), they lived an average of 11% longer than control counterparts. Longevity interventions that hold up well even in late-life are few and far between, and even the traditionally successful method of caloric restriction has limited utility when begun late.

Continue reading “Rapamycin: An impressive geroprotector with a few fatal flaws” »

A review of senescent cell removal therapies.

Aging at the cellular level is called “cell senescence”, and it contributes profoundly to whole-body aging. The most promising near-term prospects for a leap in human life expectancy come from drugs that eliminate senescent cells. Programs in universities and pharmaceutical labs around the world are racing to develop “senolytic” drugs, defined as agents that can kill senescent cells with minimal harm to normal cells.

Apoptosis is cell suicide, and (from the perspective of the full organism) it’s the best thing that can happen to senescent cells. The authors of this newest Dutch study ask how it is that senescent cells escape apoptosis.

Continue reading “Senolytics against Aging: Snapshot of a Fast-Moving Field” »

Some fear that expensive rejuvenation treatments would give rise to discrimination, but what about the discrimination against old people resulting from not developing rejuvenation?

It’s been quite a while since I posted anything new. I’ve been quite busy lately with a lot of things, including rebooting looking4troubles, my other blog. As a result, my topic list for Rejuvenaction has been growing dangerously long, so I decided it’s about time I tackled some of the lengthiest items on my list.

People like talking about justice, equality, and discrimination a lot. I mean a lot. In my experience, though, most tend to focus mainly or entirely on the type(s) of discrimination they’re more interested in for whatever reason, sometimes minimising others or not even noticing they exist in the first place. Some other times, they even end up endorsing one type of discrimination for the sake of warding off another.

As if poor people cared

Continue reading “Not all discriminations are born equal” »

DNA damage reversed in mice. Humans are next.

Scientists reverse aging in mice by repairing DNA damage. Human trials are on the cards in the next six months.

Scientists have uncovered a critical step in DNA repair and cellular aging.

Researchers have developed a line immortal stem cells that allow them to generate an unlimited supply of artificial red blood cells on demand.

If these artificial blood cells pass clinical trials, they’ll be far more efficient for medical use than current red blood cell products, which have to be generated from donor blood — and would be a huge deal for patients with rare blood types, who often struggle to find matching blood donors.

The idea isn’t for these immortal stem cells to replace blood donation altogether — when it comes to regular blood transfusions, donated blood still does the trick.

Continue reading “Immortal Stem Cells Let Scientists Create an Unlimited Supply of Artificial Blood” »

An exclusive interview with Ichor, the biotech company pioneering a SENS based repair therapy that could help cure age related blindness.

Check out our exclusive interview with Ichor the company taking the first SENS based therapy to the clinic. Should clinical trials be a success this will mark the arrival of a technology that addresses one of the aging processes.